While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Hosted on MSN
InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in pyoderma gangrenosum after trial halt
InflaRx ( (IFRX)) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma gangrenosum (PG), a rare, difficult-to-treat ulcerative ...
JENA, Germany, Dec. 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today outlined ...
In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.
It might be time to toss some of those salad dressings you have in your fridge. The FDA issued a salad dressing recall across 27 states due to “foreign objects” found in some of the batches. Although ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback